Thyroid-specific gene expression is differentially influenced by intracellular glutathione level in FRTL-5 cells

Endocrinology. 2000 Mar;141(3):901-9. doi: 10.1210/endo.141.3.7388.

Abstract

Alteration of the redox potential has been proposed as a mechanism influencing gene expression. Reduced glutathione (GSH) is one of the cellular scavengers involved in the regulation of the redox potential. To test the role that GSH may play in thyroid cells, we cultured a differentiated rat thyroid cell strain (FRTL-5) in the presence of L-buthionine-(S,R)-sulfoximine (BSO). BSO affects GSH synthesis by irreversibly inhibiting gamma-glutamylcysteine synthetase (EC 6.3.2.2), a specific enzyme involved in GSH synthesis. BSO-treated FRTL-5 cells show a great decrease in the GSH level, whereas malondialdehyde increases in the cell culture medium as a sign of lipid peroxidation. In these conditions the activity of two thyroid-specific promoters, thyroglobulin (Tg) and thyroperoxidase (TPO), is strongly reduced in transient transfection experiments. As both Tg and TPO promoters depend upon the thyroid-specific transcription factors, thyroid-specific transcription factor-1 (TTF-1) and Pax-8 for full transcriptional activity, we tested whether reduction of GSH concentration impairs the activity of these transcription factors. After BSO treatment of FRTL-5 cells, both transcription factors fail to trans-activate the respective chimerical targets, C5 and B-cell specific activating protein promoters, containing, respectively, multimerized TTF-1- or Pax-8-binding sites only as well as the Tg and TPO natural promoters. Northern analysis revealed that endogenous Tg messenger RNA (mRNA) expression is also reduced by BSO treatment, whereas endogenous TPO expression is not modified. Furthermore, the Pax-8 mRNA steady state concentration does not change in BSO-treated cells, whereas TTF-1 mRNA slightly decreases. Immunoblotting analysis of FRTL-5 nuclear extracts does not show significant modification of the Pax-8 concentration in BSO-treated cells, whereas a decrease of 25% in TTF-1 protein is revealed. Furthermore, BSO treatment decreases the DNA-binding activity to the respective consensus sequence of both transcription factors. Finally, different mechanisms seem to act on TTF-1 and Pax-8 functional impairment in BSO-treated cells. Indeed, with a lowered GSH concentration, the overexpressed Pax-8 still activates transcription efficiently, whereas, on the contrary, the overexpressed TTF-1 does not recover its transactivation capability when the respective chimerical target sequences are used (C5 and BSAP). When the natural Tg and TPO promoter sequences are used, overexpression of Pax-8 parallels the effect on both promoters observed using the chimeric target sequences, whereas overexpression of TTF-1 increases TPO promoter transcriptional activity only.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimetabolites / pharmacology
  • Blotting, Northern
  • Buthionine Sulfoximine / pharmacology
  • Cell Differentiation / physiology
  • Cell Line
  • DNA Probes / genetics
  • DNA-Binding Proteins / genetics
  • Densitometry
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Gene Expression / genetics*
  • Glutathione / metabolism*
  • Half-Life
  • Lipid Peroxidation / genetics
  • Nuclear Proteins / genetics
  • PAX8 Transcription Factor
  • Paired Box Transcription Factors
  • Plasmids / genetics
  • Promoter Regions, Genetic / genetics
  • Rats
  • Thyroid Gland / metabolism*
  • Thyroid Nuclear Factor 1
  • Trans-Activators / genetics
  • Transcription Factors / genetics
  • Transcriptional Activation / genetics
  • Transfection / genetics

Substances

  • Antimetabolites
  • DNA Probes
  • DNA-Binding Proteins
  • Nkx2-1 protein, rat
  • Nuclear Proteins
  • PAX8 Transcription Factor
  • Paired Box Transcription Factors
  • Pax8 protein, rat
  • Thyroid Nuclear Factor 1
  • Trans-Activators
  • Transcription Factors
  • Buthionine Sulfoximine
  • Glutathione